Typical Price Gap for Tigecycline Generics vs. Brand Tygacil
Generics of tigecycline, the active ingredient in Pfizer's branded Tygacil, cost 70-90% less than the brand-name version. Branded Tygacil vials (50 mg) wholesale around $100-150 per vial in the U.S., while generic equivalents from manufacturers like Fresenius Kabi or Gland Pharma sell for $10-40 per vial, depending on pharmacy and volume.[1][2]
How Prices Compare in Real-World Purchases
Hospital procurement data shows even steeper gaps: a full course of Tygacil (typically 100 mg loading dose, then 50 mg twice daily for 5-14 days) runs $2,000-$5,000, versus $400-$1,200 for generics. Patient out-of-pocket costs drop further with insurance or assistance programs, often under $50 for generics vs. hundreds for brand.[3]
Why the Price Difference Exists
Tygacil's patents expired in 2021-2022, enabling multiple generic approvals by the FDA (e.g., Aurolife in 2021, others in 2023). No pediatric exclusivity remains, so generics face minimal barriers. Pfizer still markets Tygacil at premium prices for its established safety profile in complicated infections.[1][4]
When Does Generic Availability Peak?
Full generic penetration hit in 2023-2024, with 5+ ANDA approvals. Market share for generics now exceeds 80% in U.S. hospitals, driving brand prices down in competitive bids but not eliminating the gap entirely.[2][5]
Factors Affecting Your Price as a Buyer
- Volume and setting: Hospitals pay lowest generic rates ($15-25/vial); retail pharmacies charge 20-50% more.
- Region: U.S. prices highest; EU/India generics as low as $5/vial.
- Shortages: Occasional tigecycline shortages (e.g., 2023) temporarily widen gaps by limiting generic supply.[3]
| Supplier Example | Brand Vial Price | Generic Vial Price | Savings |
|------------------|------------------|--------------------|---------|
| Tygacil (Pfizer) | $120 | N/A | - |
| Fresenius Generic| N/A | $25 | 79% |
| Gland Generic | N/A | $18 | 85% |[2][6]
Patent Status and Future Pricing
Core tigecycline patents ended December 2021 (U.S. Patent 7,115,584). Remaining formulation patents (e.g., 10,543,179) expire 2028-2030 but face challenges; no injunctions block generics now. Expect gaps to narrow to 90%+ by 2026 as competition grows.[1][4]
Sources
[1]: DrugPatentWatch.com - Tygacil Patents
[2]: IQVIA National Sales Perspectives, 2024
[3]: FDA Orange Book and shortage list
[4]: DrugPatentWatch.com - Tigecycline Generics
[5]: Generics Bulletin, Q1 2024
[6]: Premier Inc. hospital procurement data